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a b s t r a c t
Background and objective: Heart rate (HR) ≥70 beats per minute (bpm) increases cardiovascular
risk in coronary artery disease (CAD) patients. The objective of the analysis is to characterize
HR as well as other clinical parameters in outpatients with stable CAD in Latvia.
Materials and methods: CLARIFY is an ongoing international registry of outpatients with
established CAD. Latvian data regarding 120 patients enrolled in CLARIFY and collected at
baseline visit during 2009–2010 were analyzed.
Results: The mean HR was 67.7  9.5 and 66.9  10.7 bpm when measured by pulse palpation
and electrocardiography, respectively. HR ≤60 bpm and ≥70 bpm was observed in 25% and
35.8% of patients, respectively. When analyzing patients with angina symptoms, 22.8% had
HR ≤60 bpm while HR ≥70 bpm was observed in 33.3% of the cases. HR ≥70 bpm was observed
in 36.2% of patients with symptoms of chronic heart failure. Beta-blockers were used in
81.7% of the patients. Metoprolol (long acting succinate), bisoprolol, nebivolol and carvedilol
in average daily doses 63.8, 5.3, 4.5, and 10.4 mg/d were used in 47, 37, 11 and 3 cases,
respectively. Among patients with HR ≥70 bpm 79.1% were using beta-blockers. Medications
did not differ signiﬁcantly between the three groups according to HR level (≤60, 61–69 and
≥70 bpm).
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Conclusions: Despite the wide use of beta-blockers, HR is insufﬁciently controlled in the
analyzed sample of stable CAD patients in Latvia. Target HR ≤60 bpm is achieved only in 25%
of the patients while more than one third have increased HR ≥70 bpm.
# 2014 Lithuanian University of Health Sciences. Production and hosting by Elsevier
Urban & Partner Sp. z o.o. All rights reserved.
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Coronary artery disease (CAD) is the main cause of mortality
worldwide [1]. Cardiovascular mortality in Latvia is higher than
in European Union on average [2]. The prospeCtive observa-
tional LongitudinAl RegIstry oF patients with stable coronary
arterY disease (CLARIFY) registry was initiated to improve
knowledge about outpatients with stable CAD: to describe this
population in terms of demographics, risk factors, management
as well outcomes; to ﬁnd out discrepancies between evidence-
based recommendations and routine treatment in practice as
well as to identify long-term prognostic determinants in CAD
outpatients [3]. Heart rate (HR) is important player in patho-
physiology of CAD. Increased HR is associated with ischemia as
it affects negatively the myocardial oxygen balance by increas-
ing oxygen consumption and decreasing oxygen supply.
Besides, large body of evidence suggests that high HR is
associated with increased cardiovascular risk [4–6]. Several
epidemiological studies underline relationship between in-
creased HR and risk of total as well as cardiovascular mortality
[4,5]. The prognostic value of high HR in stable CAD patients with
left ventricular dysfunction has been conﬁrmed also in a
prospective way in the BEAUTIFUL trial. Analysis of a large
cohort from the placebo arm in the BEAUTIFUL study showed
strong association of HR ≥70 beats per minute (bpm) with higher
risk of cardiovascular events [6]. Beta-blockers, agents providing
efﬁcient HR reduction, is well established class in treatment of
stable CAD and clinical beneﬁts of HR reduction with beta-
blockers are well known. However, besides HR reduction beta-
blockers have many other effects such us blood pressure
reduction, negative inotropic effect etc. [7]. There is also an
evidence of clinical improvement in angina symptoms with
pure heart rate reducing agent [8,9]. BEAUTFUL study showed
that pure HR lowering strategy in stable CAD patients may
reduce coronary events [10,11]. By recognizing HR as the risk
factor and deﬁning reduction of HR <60 bpm as important goal
of treatment CAD patients, the newest European guidelines on
stable CAD (2013) establish role of HR control in management of
stable CAD [12]. The objective of the current study is to analyze
actually achieved HR level, to evaluate proportion of patients in
whom HR targets are not reached despite treatment and to
analyze other clinical parameters in routinely managed out-
patients with stable CAD in Latvia.
2. Materials and methods
CLARIFY is an ongoing international, prospective, observa-
tional longitudinal registry of outpatients with establishedCAD in which patients are followed-up for 5 years. A total of
33,438 patients from 45 countries worldwide were included in
the registry. The rationale of the registry was based on need to
collect data on the current status of outpatients with stable
CAD [3]. Worldwide baseline data of the registry have been
published previously [13]. In Latvia, 120 patients with
established CAD were included in CLARIFY registry during
2009 and 2010. Patients were managed according to usual
clinical practice by treating physicians. No speciﬁc examina-
tions or treatment changes were introduced.
Patients were eligible for enrollment if at least one of the
inclusion criteria was presented: documented myocardial
infarction (more than 3 months ago), coronary stenosis more
than 50% on coronary angiography, chest pain in combination
with myocardial ischemia (conﬁrmed by stress electrocardio-
gram (ECG), stress echocardiography or myocardial imaging),
coronary revascularization (coronary artery bypass graft
(CABG) or percutaneous coronary intervention (PCI)) at least
3 months ago. Exclusion criteria were hospitalization due to
cardiovascular disease within last 3 months, planned revas-
cularization and conditions expected to interfere participation
or 5-year follow-up.
Twelve physicians (cardiologists and general practitioners
treating CAD outpatients) each enrolled 10 patients on
average. During baseline visit the following data were collected:
demographic information, medical history, risk factors and
lifestyle, physical examination data (including HR), current
symptoms, most recent laboratory values as well as information
about current medical treatment. The resting HR was estimated
by pulse palpation and electrocardiography (ECG). HR by pulse
palpation was measured for 30 s after sitting for at least 5 min in
a quiet room with comfortable temperature. Two different
measurements were taken, and the second was recorded. For
ECG the most recent 12-lead ECG within 6 months was analyzed.
For evaluation of angina symptoms Canadian Cardiovascular
Society (CCS) classiﬁcation was used. New York Heart Associa-
tion (NYHA) classiﬁcation was used to assess severity of heart
failure symptoms. Laboratory values (e.g. fasting blood glucose,
cholesterol, triglycerides) were collected if given date were
available. Patients were managed according to usual clinical
practice at each institution with no speciﬁc tests deﬁned in the
protocol.
Data were collected by using standardized, international case
report form translated into Latvian. Completed electronic case
report forms using these data were sent to the data management
center in Glasgow. Approval of the Ethics Committee of the
Research Institute of Cardiology, University of Latvia was
obtained before enrollment of patients into registry.
All CLARIFY data are stored and analyzed at the Robertson
Center for Biostatistics, University of Glasgow, UK. Continuous
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or median and interquartile range (IQR) depending on the
distribution of the data. Categorical data are summarized using
counts and percentages. Summaries are provided for the total
CLARIFY Latvia data overall and split into three mutually
exclusive groups of patients' according to HR (measured by
palpation) level: with HR ≤60, 61–69 and ≥70 bpm. In order to
analyze clinical characteristics and medications according to
HR level, P values for differences between the groups were
calculated using either the chi-square test or Fisher exact test for
the categorical variables, depending on the data, and for the
continuous variables using either one-way analysis of variance,
or Kruskal–Wallis test, depending on the distribution of the
data. The correlation between the different heart rate measure-
ments was calculated using Pearson correlation. Statistical
analyses were performed using the Statistical Analysis Software
(SAS) (version 9.2). A signiﬁcance level of 0.05 was used to test for
statistical differences throughout and all tests used were two-
sided.
HR ≥70 bpm was assessed as increased in accordance with
recent evidence [10,14,15]. Target HR <60 bpm was deﬁned in
accordance with 2013 European stable CAD guidelines [12].
Height and weight were used to calculate body mass index
in kg/m2.
Permission to publish national data of CLARIFY registry
was obtained from Les Laboratoires Servier (global sponsor of
CLARIFY registry) and Servier Latvia (sponsor of CLARIFY
registry on national level in Latvia) before publishing data.
3. Results
Characteristics of CLARIFY population in Latvia are summa-
rized in Table 1. Mean age of patients was 64.2  7.9 years;
most of them were men (72.5%) (Table 1). Distribution of HR
when measured by pulse palpation is shown in Fig. 1. Mean HR
was 67.7  9.5 bpm and 66.9  10.7 bpm when measured by
pulse palpation and ECG, respectively. A strong correlation
between HR measured by pulse palpation and ECG-derived HR
was found (r = 0.848, P < 0.001) (Fig. 2).
Ethnicity of all patients was Western descent, most of them
were retired (50.8%) and most commonly the level of education
was secondary school (57.5%). The median time since diagnosisFig. 1 – Distribution of Latvian patients with stable CAD by
heart rate (cohort of Latvian patients, included in the
worldwide registry CLARIFY).of CAD was 4 (IQR 2–10) years. The most common risk factors
were dyslipidemia (94.2%) and treated hypertension (78.3%); the
majority of patients were nonsmokers (41.7%); most frequently
alcohol intake was >0 and <20 drinks per week (65.0%); from
stimulant drinks coffee was more consumed than tea (59.2%
and 39.2% respectively) and regarding physical activity most of
the patients had light physical activity most weeks (45.8%)
(Table 1). Chronic heart failure symptoms were present more
frequently than symptoms of angina (57.5% compared to 47.5%);
most frequently coronary territories with stenosis >50% at
coronary angiography or having required revascularization in
the past were in left anterior descending (69.2%) and most of the
patients were in sinus rhythm (95.8%) (Table 1). Patients were
divided in to three groups according to baseline HR by pulse
palpation: ≤60 bpm, 61–69 bpm and ≥70 bpm. The clinical
characteristics of these three subgroups are summarized in
Table 1. When analyzing clinical characteristics, only diastolic
blood pressure and the presence of coronary stenosis >50% in
right coronary artery at coronary angiography differed signiﬁ-
cantly between three HR groups (Table 1). Patients with higher
HR had higher diastolic blood pressure (Table 1). Among all
57 patients with angina, 22.8% had HR ≤60 bpm, but HR ≥70 bpm
was observed in 33.3% of cases while among patients with
chronic heart failure (n = 69), HR ≤60 bpm was observed in 27.5%
of cases, but in 29.0% of patients HR was ≥70 bpm.
The use of medication in total population as well as in three
HR subgroups is summarized in Table 2. With respect of HR
lowering agents, the most frequently used were beta-blockers
(81.7%). Metoprolol (long acting succinate) and bisoprolol were
used in 47 and in 37 cases, respectively. Nebivolol and
carvedilol were used in 11 and 3 cases, respectively. Average
daily dose used for metoprolol, bisoprolol, nebivolol and
carvedilol were 63.8, 5.3, 4.5, and 10.4 mg/d, respectively.
Ivabradine was used in 11.7% of the cases, while digoxin and
amiodarone or dronedarone were used in 2.5% and 4.2% of the
cases, respectively (Table 2). Calcium antagonists with HR-
lowering effect (verapamil or diltiazem) were not used at all.
No signiﬁcant differences in terms of medications were found
between three groups of patients with different resting HR
level (Table 2). There was no difference between the median
number of HR lowering agents and the IQR between the HR
groups, or the number of antianginals (median number of HR
lowering agents and the number of antianginals was 1 (IQR 1–1)
and 2 (IQR 1–2), respectively).
Differences in HR level in groups of patients using or not
beta-blockers are shown in Fig. 3. Mean HR when measured by
pulse palpation in patients using beta-blockers and in those
not receiving any beta-blocker was 67.3  9.8 bpm and
69.4  8.0 bpm, respectively; when measured by ECG HR was
66.2  11.1 and 70.1  8.4 in patients with and without beta-
blockers, respectively. However, HR differences in patients with
as opposed to without beta-blockers did not reach statistical
signiﬁcance (by palpation: P = 0.356; by ECG: P = 0.131). Propor-
tion of patients with HR ≥70 bpm among patients using and not
using beta-blockers was 34.7% and 40.9%, respectively
(P = 0.627). Systolic as well as diastolic blood pressure was
lower in patients using beta-blockers: systolic blood pressure
with and without beta-blockers was 136.1  16.4 mm Hg and
148.1  17.2 mm Hg, respectively (P = 0.003); diastolic blood
pressure with and without beta-blockers was 82.2  8.4 mm


















Age, mean  SD, years 120 64.2  7.9 64.7  7.6 64.0  7.3 64.1  9.0 0.929
Men, n (%) 120 87 (72.5) 23 (76.7) 33 (70.2) 31 (72.1) 0.824
Body mass index,
median (IQR), kg/m2
120 28.8 (26.2–32.0) 29.9 (27.9–32.9) 28.1 (25.9–31.6) 29.1 (25.7–33.7) 0.114
Waist circumference,
median (IQR), cm
120 101.0 (95.0–109.0) 101.5 (95.0–110.0) 100.0 (96.0–106.0) 102.0 (93.0–111.0) 0.869
Medical history, n (%)
Myocardial infarction 120 76 (63.3) 17 (56.7) 29 (61.7) 30 (69.8) 0.498
PCI 120 89 (74.2) 26 (86.7) 35 (74.5) 28 (65.1) 0.117
CABG 120 29 (24.2) 8 (26.7) 10 (21.3) 11 (25.6) 0.834
ICD 120 0 (0) 0 (0) 0 (0) 0 (0) –
Pacemaker 120 3 (2.5) 1 (3.3) 1 (2.1) 1 (2.3) 1.000
Hospitalization for CHF 120 2 (1.7) 1 (3.3) 0 (0) 1 (2.3) 0.520
Stroke 120 3 (2.5) 0 (0) 1 (2.1) 2 (4.7) 0.619
Atrial ﬁbrillation/ﬂutter 120 12 (10.0) 2 (6.7) 4 (8.5) 6 (14.0) 0.588
Asthma/COPD 120 7 (5.8) 2 (6.7) 3 (6.4) 2 (4.7) 1.000
Risk factors and life style, n (%)
Family history of
premature CADa
120 29 (24.2) 5 (16.7) 12 (25.5) 12 (27.9) 0.523
Treated hypertension 120 94 (78.3) 24 (80.0) 38 (80.9) 32 (74.4) 0.736
Diabetes 120 25 (20.8) 6 (20.0) 12 (25.5) 7 (16.3) 0.554
Dyslipidemia 120 113 (94.2) 26 (86.7) 46 (97.9) 41 (95.3) 0.122
PAD 120 8 (6.7) 2 (6.7) 2 (4.3) 4 (9.3) 0.592
Smoking status, n (%)
Current 120 21 (17.5) 2 (6.7) 9 (19.1) 10 (23.3) 0.194**
Former 120 49 (40.8) 16 (53.3) 15 (31.9) 18 (41.9)
Never 120 50 (41.7) 12 (40.0) 23 (48.9) 15 (34.9)
Alcohol intake (drinks/week), n (%)
0 120 38 (31.7) 9 (30.0) 15 (31.9) 14 (32.6) 1.000**
>0 and <20 120 78 (65.0) 20 (66.7) 30 (63.8) 28 (65.1)
20–40 120 4 (3.3) 1 (3.3) 2 (4.3) 1 (2.3)
Stimulant drinks consumed, n (%)
Coffee 120 71 (59.2) 16 (53.3) 25 (53.2) 30 (69.8) 0.320**
Tea 120 47 (39.2) 13 (43.3) 21 (44.7) 13 (30.2)
Neither 120 2 (1.7) 1 (3.3) 1 (2.1) 0 (0)
Physical activity
None 120 8 (6.7) 4 (13.3) 2 (4.3) 2 (4.7) 0.418**
Lightb 120 55 (45.8) 12 (40.0) 26 (55.3) 17 (39.5)
1–2 times/weekc 120 21 (17.5) 6 (20.0) 8 (17.0) 7 (16.3)
≥3 times/weekc 120 36 (30.0) 8 (26.7) 11 (23.4) 17 (39.5)
Angina, n (%) 120 57 (47.5) 13 (43.3) 25 (53.2) 19 (44.2) 0.604
CCS class if angina, n (%)
Class I 57 16 (28.1) 6 (46.2) 7 (28.0) 3 (15.8) 0.324**
Class II 57 36 (63.2) 7 (53.8) 16 (64.0) 13 (68.4)
Class III 57 5 (8.8) 0 (0) 2 (8.0) 3 (15.8)
CHF symptoms, n (%) 120 69 (57.5) 19 (6) 25 (53.2) 25 (58.1) 0.676
NYHA class if CHF, n (%)
Class II 69 62 (89.9) 18 (94.7) 24 (96.0) 20 (80.0) 0.162**
Class III 69 7 (10.1) 1 (5.3) 1 (4.0) 5 (20.0)
Creatinine, median (IQR),
mmol/L
94 0.085 (0.073–0.100) 0.084 (0.074–0.102) 0.087 (0.072–0.099) 0.086 (0.074–0.112) 0.654
Blood glucose,
median (IQR), mmol/L
107 5.7 (5.2–6.4) 5.8 (5.5–6.1) 5.7 (5.3–6.8) 5.6 (5.0–6.1) 0.119
Total cholesterol,
median (IQR), mmol/L
113 4.5 (3.9–5.1) 4.4 (3.8–4.8) 4.6 (3.9–5.2) 4.5 (4.0–5.3) 0.329
HDL-C, median (IQR), mmol/L 102 1.2 (1.0–1.5) 1.3 (0.9–1.4) 1.2 (1.1–1.6) 1.2 (1.0–1.5) 0.572
LDL-C, median (IQR), mmol/L 104 2.6 (2.0–3.1) 2.5 (1.7–2.9) 2.7 (2.0–3.6) 2.5 (2.0–3.1) 0.365
Triglycerides,
median (IQR), mmol/L
108 1.4 (1.0–2) 1.4 (1.1–1.9) 1.3 (1.0–1.8) 1.6 (1.1–2.1) 0.695
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mean  SD, bpm
120 67.7  9.5 57.4  3.0 65.1  2.1 77.8  7.6 –
ECG heart rate,
mean  SD, bpm
119 66.9  10.7 56.0  4.5 65.7  6.3 75.8  10.1 –
SBP, mean  SD, mm Hg 120 138.3  17.1 136.0  17.7 138.1  14.7 140.0  19.3 0.621
DBP, mean  SD, mm Hg 120 83.0  8.6 79.6  7.7 83.9  8.0 84.3  9.2 0.043*
LVEF, mean  SD, % 96 57.1  8.7 58.4  8.7 58.5  8.2 54.6  8.8 0.107
Presence of coronary stenosis >50%
Left main stenosisd, n (%) 120 13 (10.8) 4 (13.3) 6 (12.8) 3 (7.0) 0.609
LAD stenosisd, n (%) 120 83 (69.2) 22 (73.3) 32 (68.1) 29 (67.4) 0.848
Cx stenosisd, n (%) 120 56 (46.7) 13 (43.3) 24 (51.1) 19 (44.2) 0.739
RCA stenosisd, n (%) 120 73 (60.8) 19 (63.3) 35 (74.5) 19 (44.2) 0.013*
CABG stenosisd, n (%) 120 19 (15.8) 5 (16.7) 8 (17.0) 6 (14.0) 0.914
No stenosis, n (%) 120 1 (0.8) 0 (0) 1 (2.1) 0 (0) 1.000
Coronary angiography
not done, n (%)
120 7 (5.8) 0 (0) 3 (6.4) 4 (9.3) 0.257
Test for myocardial
ischemiae, n (%)
120 108 (90.0) 26 (86.7) 44 (93.6) 38 (88.4) 0.543
Current evidence of
ischemia, n (%)
120 8 (6.7) 3 (10.0) 4 (8.5) 1 (2.3) 0.372
ECG rhythm, n (%)
Sinus rhythm 119 114 (95.8) 28 (93.3) 45 (97.8) 41 (95.3) 0.397**
Atrial ﬁbrillation/ﬂutter 119 3 (2.5) 1 (3.3) 0 (0) 2 (4.7)
Paced rhythm 119 2 (1.7) 1 (3.3) 1 (2.2) 0 (0)
bpm, beats per minute; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CHF, chronic
heart failure; COPD, chronic obstructive pulmonary disease; Cx, circumﬂex; DBP, diastolic blood pressure; ECG, electrocardiogram; HDL-C, high-
density lipoprotein cholesterol; HR, heart rate; ICD, internal cardiac deﬁbrillator; IQR, interquartile range; LAD, left anterior descending; LDL-C,
low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAD, peripheral arterial
disease; PCI, percutaneous coronary intervention; RCA, right coronary artery; SBP, systolic blood pressure.
a Myocardial infraction, sudden death, stable angina at age <55 years (men) or 65 years (women) in a ﬁrst-degree relative.
b Light physical activity most weeks.
c At least 20-min vigorous physical activity.
d Coronary territories with stenosis >50% at coronary angiography or having required revascularization in the past.
e Noninvasive test for myocardial ischemia (stress ECG, stress echocardiography, myocardial imaging).
* Statistically signiﬁcant.
** P value calculated for distribution of patients according to HR level into different groups of given variable.
m e d i c i n a 5 0 ( 2 0 1 4 ) 2 9 5 – 3 0 2 299Hg and 86.6  8.5 mm Hg, respectively (P = 0.030). Patients using
beta-blockers less frequently had family history of premature
CAD (17.3% vs. 54.5%, P < 0.001) and more frequently had
medical history of PCI (80.6% vs. 45.5%, P < 0.001) than those not
using beta-blockers. In patients not using beta-blockers,
coronary angiography was not done more frequently compared
with those who were using beta-blockers (22.7% vs.
2%, P = 0.002). Comparison of patients using and not using
beta-blockers also showed that of those not on beta-blockers,
symptoms indicative of intolerance or contraindication to beta-
blockers as well as the usage of ivabradine was more frequent
than for those patients who were on beta-blockers (59.1% vs.
12.2%, P < 0.001 for intolerance of beta blockers and 50.0% vs.
3.1%, P < 0.001 for usage of ivabradine, respectively). The
median number of HR-lowering agents in group of patients
using and not using beta-blockers was 1 (IQR 1–1) and 1 (IQR 0–1),
respectively (P < 0.001). Number of antianginal agents and
number of antianginal or HR lowering agents also differedsigniﬁcantly between two groups according to beta-blockers
usage: median number of antianginal agents was higher in
group of patients using beta-blockers (2 [IQR 1–2] vs. 1 [IQR 0–2],
P < 0.001) as well as median number of antianginal or HR
lowering agents (2 [IQR 2–2] vs. 1 [IQR 1–2], P < 0.001).
4. Discussion
By giving description of HR in the analyzed sample of stable
CAD patients, this study elucidates insufﬁcient control of HR in
treated stable CAD population. Despite the fact, that absolute
majority of patients receive beta-blockers, more than one third
still have increased resting HR ≥70 bpm which is the level
associated with higher risk of cardiovascular events in CAD
patients [11]. According to European guidelines on management
of stable CAD 2013, target HR in stable CAD patients is <60 bpm
[12]. In the analyzed sample proportion of patients with HR
Fig. 2 – Association between pulse HR and ECG HR in Latvian patients (cohort of Latvian patients, included in the worldwide
registry CLARIFY).
m e d i c i n a 5 0 ( 2 0 1 4 ) 2 9 5 – 3 0 2300≤60 bpm is smaller than proportion of patients with increased
HR ≥70 bpm. Increased HR in angina patients not only has
negative impact on prognosis but also is pathophysiologically
linked with ischemia. That is why situation with HR control in
analyzed CAD patients with angina symptoms seems even
worse. One third of angina patients are with increased HR
≥70 bpm and only in 22.8% of cases HR level ≤60 bpm is reached.
Proportion of patients with increased HR among CHD patients
with present symptoms of chronic heart failure is also around
one third despite the fact that increased HR has been proved toTable 2 – Medications of the study population classified accord




(n = 120) ≤60 bpm
Aspirin, n (%) 117 (97.5) 29 (9
Thienopyridine, n (%) 18 (15.0) 7 (2
Other antiplatelets, n (%) 1 (0.8) 1 (3
Oral anticoagulants, n (%) 4 (3.3) 1 (3
Beta-blockers, n (%) 98 (81.7) 26 (8
Symptoms indicative of intolerance or
contraindication to beta-blockers, n (%)
25 (20.8) 8 (2
Ivabradine, n (%) 14 (11.7) 1 (3
Calcium antagonists, n (%)a 65 (54.2) 20 (6
Angiotensin-converting enzyme
inhibitors, n (%)
86 (71.7) 25 (8
Angiotensin II receptor blockers, n (%) 17 (14.2) 3 (1
Lipid-lowering drug, n (%) 114 (95.0) 27 (9
Long-acting nitrates, n (%) 28 (23.3) 4 (1
Other antianginal agents, n (%) 15 (12.5) 5 (1
Diuretics, n (%) 31 (25.8) 10 (3
Other antihypertensive agents, n (%) 11 (9.2) 4 (1
Digoxin and derivatives, n (%) 3 (2.5) 1 (3
Amiodarone/dronedarone, n (%) 5 (4.2) 2 (6
Other antiarrythmics, n (%) 4 (3.3) 1 (3
Antidiabetic agents, n (%) 23 (19.2) 5 (1
HR, heart rate.
a Dihidropiridine calcium antagonists.be risk factor in heart failure patients [16]. Even among patients
on beta-blockers proportion of patients with increased HR
≥70 bpm was more than one third and did not differ signiﬁcantly
from those not on beta-blockers. CLARIFY data from Latvian
population are fully comparable to worldwide CLARIFY data
[13]. A total 33,177 CAD patients from 45 countries have been
analyzed in the CLARIFY registry. In Latvian population
proportion of patients with increased HR ≥70 bpm is smaller
than in global CLARIFY population (35.8% vs. 44.0%) as well as
proportion of patients with HR ≥70 bpm among patients oning to resting heart rate by palpation.
Population according to palpation HR P
 (n = 30) 61–69 bpm (n = 47) ≥70 bpm (n = 43)
6.7) 45 (95.7) 43 (100) 0.468
3.3) 7 (14.9) 4 (9.3) 0.256
.3) 0 (0) 0 (0) 0.250
.3) 0 (0) 3 (7.0) 0.130
6.7) 38 (80.9) 34 (79.1) 0.699
6.7) 8 (17.0) 9 (20.9) 0.597
.3) 7 (14.9) 6 (14.0) 0.257
6.7) 26 (55.3) 19 (44.2) 0.162
3.3) 34 (72.3) 27 (62.8) 0.158
0.0) 7 (14.9) 7 (16.3) 0.738
0.0) 47 (100) 40 (93.0) 0.070
3.3) 10 (21.3) 14 (32.6) 0.147
6.7) 7 (14.9) 3 (7.0) 0.383
3.3) 9 (19.1) 12 (27.9) 0.355
3.3) 3 (6.4) 4 (9.3) 0.565
.3) 0 (0) 2 (4.7) 0.352
.7) 1 (2.1) 2 (4.7) 0.631
.3) 2 (4.3) 1 (2.3) 1.000
6.7) 12 (25.5) 6 (14.0) 0.349
Fig. 3 – Distribution of Latvian patients with and without
beta-blockers use by heart rate (cohort of Latvian patients,
included in the worldwide registry CLARIFY). The vertical
lines represent the minimum and maximum values. The
box represents the lower (25th percentile) and upper (75th
percentile) quartiles. Within the box, the vertical line is the
median and the diamond the mean. Values 1.5 times the
interquartile range were considered outliers and are
shown as individual circles.
m e d i c i n a 5 0 ( 2 0 1 4 ) 2 9 5 – 3 0 2 301beta-blockers (34.7% vs. 41.1%). The Latvian sample studied
CLARIFY is also comparable to EuroHeart Survey population
where 156 cardiology clinics from 34 countries participated and
more than 3000 patients with diagnosis of stable angina were
analyzed [17]. Investigators of EuroHeart Survey showed that
proportion of patients with HR >70 bpm in analyzed angina
population is 52.3% despite treatment [18]. On one hand it seems
encouraging and likely showing that HR control in analyzed
Latvian CAD patients is better than in other countries. On the
other side we should take into account that situation in Latvia
with cardiovascular mortality is not favorable and is higher than
in European Union on average [2]. Therefore all signs of
insufﬁcient control of CAD risk factors (including HR) should
be seriously analyzed. Proportion of angina patients with HR
≤60 bpm in our sample is similar to worldwide CLARIFY data [13]
(22.8% vs. 22.1%) and is in line with observations in the
EuroHeart Survey where only 19% of angina patients had HR
≤62 bpm [18]. These ﬁndings are a warning and have important
clinical implications. HR remains above the level associated with
higher risk of cardiovascular events in CAD patients in a
substantial proportion of CAD patients. This indicates need for
further improvement of HR control in CAD patients. Education of
physicians regarding negative impact of increased HR on
prognosis as well as wide communication about statement of
guidelines [12] that the target HR in stable CAD is <60 bpm could
be an important part in further improvement of HR control in
Latvia.
Usage of beta-blockers does not fully solve the problem of
increased resting HR as most of the analyzed CLARIFY Latvian
patients were on beta-blockers. It is in line with global CLARIFY
data [13] and could be explained by insufﬁcient dosage of beta-
blockers as underdose of these agents is typical in communityand associated with poor long-term compliance [19]. Combi-
nation of beta-blockers with ivabradine could be a step further
toward a better HR control in CAD patients. Our ﬁndings show
a potential for better control of HR and encourage use of
available tools in order to improve control of this risk factor for
further improvement of symptoms and prognosis in CAD
patients in Latvia.
Limitations for interpretation of our data should be
acknowledged as the analyzed sample of CAD patients includes
relatively small number of patients. Selection bias may also
have taken place during the enrollment of patients into CLARIFY
and therefore the study population may not fully reﬂect the
situation for the total population of stable CAD patients in
Latvia. For a better understanding of the situation with HR
control in CAD patients in Latvia, studies with larger number of
included patients are needed. Long term observations with
follow-up period are preferable to evaluate changes in manage-
ment of HR over a period of time.
5. Conclusions
Despite the wide use of beta-blockers, HR is insufﬁciently
controlled in analyzed sample of stable CAD patients in Latvia.
HR ≤60 bpm is achieved only in 25% of analyzed CAD patients
and 22.8% of patients with angina symptoms while more than
one third has increased HR ≥70 bpm. The ﬁndings elucidate
underusage of HR controlling agents and a great potential for
targeting HR as the risk factor and determinant of symptoms.
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